Brokerages Expect ContraFect Corp (CFRX) to Post -$0.10 EPS
Analysts expect ContraFect Corp (NASDAQ:CFRX) to report ($0.10) earnings per share (EPS) for the current fiscal quarter, Zacks reports. Zero analysts have provided estimates for ContraFect’s earnings, with estimates ranging from ($0.10) to ($0.09). ContraFect posted earnings per share of $0.04 in the same quarter last year, which indicates a negative year-over-year growth rate of 350%. The company is scheduled to report its next quarterly earnings report on Thursday, November 8th.
According to Zacks, analysts expect that ContraFect will report full year earnings of ($0.64) per share for the current financial year, with EPS estimates ranging from ($0.72) to ($0.39). For the next fiscal year, analysts forecast that the business will post earnings of ($0.40) per share, with EPS estimates ranging from ($0.45) to ($0.35). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side analysts that that provide coverage for ContraFect.
ContraFect (NASDAQ:CFRX) last issued its quarterly earnings results on Thursday, August 9th. The biotechnology company reported ($0.27) EPS for the quarter, missing the consensus estimate of ($0.10) by ($0.17).
Shares of NASDAQ:CFRX traded up $0.11 during trading on Monday, hitting $1.73. 3,552 shares of the company’s stock were exchanged, compared to its average volume of 152,922. ContraFect has a 1-year low of $0.85 and a 1-year high of $2.93. The stock has a market cap of $128.64 million, a price-to-earnings ratio of -4.68 and a beta of -0.45.
Large investors have recently modified their holdings of the company. Acadian Asset Management LLC acquired a new stake in shares of ContraFect during the 2nd quarter worth approximately $111,000. DRW Securities LLC grew its position in shares of ContraFect by 37.5% during the 1st quarter. DRW Securities LLC now owns 110,000 shares of the biotechnology company’s stock worth $179,000 after buying an additional 30,000 shares during the period. JPMorgan Chase & Co. acquired a new stake in shares of ContraFect during the 1st quarter worth approximately $131,000. Finally, Renaissance Technologies LLC grew its position in shares of ContraFect by 40.6% during the 2nd quarter. Renaissance Technologies LLC now owns 200,500 shares of the biotechnology company’s stock worth $443,000 after buying an additional 57,900 shares during the period. Institutional investors own 54.72% of the company’s stock.
ContraFect Corporation, a clinical-stage biotechnology company, focuses on discovering and developing therapeutic protein and antibody products for the treatment of life-threatening infectious diseases in the United States. Its lead product candidates consist of CF-301, a lysin that is in Phase II human clinical trials for the treatment of Staphylococcus aureus bacteremia, including endocarditis caused by methicillin-resistant or methicillin-susceptible; and CF-404, a combination of monoclonal antibodies (mAbs), which is in preclinical trial stage for the treatment of life-threatening seasonal and pandemic varieties of human influenza.
Read More: Market Capitalization
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ContraFect Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ContraFect and related companies with MarketBeat.com's FREE daily email newsletter.